London +4420 814 42225
Moscow +7495 543 9194
Kiev +38044 599 2950

Our Clients

Order Informer

Home > News >

Merck KGaA appoints new chairman, CEO

September 30/2020

MOSCOW  (MRC) -- Merck KGaA says that Stefan Oschmann, the company’s chairman and CEO since 2016, will hand over his responsibilities to Belen Garijo on 1 May 2021, said Chemweek.

Garijo has been appointed Merck’s new chair and CEO by the company’s board of partners. Garijo is currently vice chair of Merck’s board and deputy CEO, as well as CEO of the company’s healthcare business. Oschmann will leave the company as planned after 10 years on the board, five of them as chairman and CEO, to turn to other tasks, the company says.

Johannes Baillou, chairman of Merck's board of partners, says that Garijo “has done excellent work in transforming our healthcare business sector. Belen Garijo and Stefan Oschmann have been collaborating closely and trustfully for many years. This will ensure a seamless transition and continuity in corporate management,” he says.

Peter Guenter will join the Merck board, effective 1 January at the latest, the company says. He will assume board responsibility for the healthcare business sector and be located at Merck's Darmstadt, Germany, headquarters. Matthias Heinzel will also join the company’s board, effective 1 April 2021 at the latest, Merck says. He will assume board responsibility for Merck’s life science business sector and be located at Burlington, Massachusetts, and Darmstadt.

Kai Beckmann and Marcus Kuhnert will remain board members, Merck says.

As MRC wrote previously, Merck KGaA has announced the opening its M Lab Collaboration Center in Shanghai, China. Merck Innovation Hub, the first in China, started in late 2019, with the company announcing a 100 million renminbi (USD14 million) seed fund injected into the China Innovation Hub.

We remind that Merck celebrated the opening of its new packaging center at the science and technology company’s headquarters in Darmstadt, Germany, in October, 2018. The new 161,458-square-foot facility is dedicated to the packaging and shipping of Merck’s current portfolio of pharma medicines in more than 90 countries and help meet increasing patient needs for flagship medicines Glucophage, Concor and Euthyrox in the areas of diabetes, cardiovascular diseases and thyroid disorders respectively. It will also provide capacity for potential future pharma products currently in clinical development such as evobrutinib in the area of neurology-immunology or tepotinib in the area of oncology.

Ethylene and propylene are feedstocks for producing polyethylene (PE) and polypropylene (PP).

According to MRC's ScanPlast report, Russia's overall PE production totalled 1,712,400 tonnes in the first seven months of 2020, up by 58% year on year. Linear low density polyethylene (LLDPE) accounted for the greatest increase in the output. At the same time, overall PP production in Russia increased in January-July 2020 by 24% year on year to 1,063,700 tonne. ZapSibNeftekhim accounted for the main increase in the output.
Author:Anna Larionova
Tags:PP, PE, Medicine, Merck.
Category:General News
| More

Leave a comment

MRC help


 All News   News subscribe